Matthias Beat Wittwer

This inventor holds 14 USPTO granted patents and 8 published patent applications and 6 EPO patents. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft. Active years: 2018-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Beat Wittwer. Retrieved from https://idiyas.com/inventor/matthias-beat-wittwer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 8)

% Patents Active = 35.7

EPO Patents = 6 (Patent Applications = 18)

Average Co-Inventor Count = 11.9

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Wuppertal, DE (2018 - 2019)
Riehen, CH (2019 - 2022)

Company Filing History:

13 out of 387

Bayer Pharma Aktiengesellschaft

patents

6 out of 12,268

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2018-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11472803 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2022-10-18),

2. 11298367 - Prodrugs of substituted triazole derivatives and uses thereof (2022-04-12),

3. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),

4. 11149023 - Substituted triazole derivatives and uses thereof (2021-10-19),

5. 11091463 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2021-08-17),

6. 10927109 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2021-02-23),

7. 10927098 - Hydroxyalkyl-substituted triazole derivatives and uses thereof (2021-02-23),

8. 10815205 - Amide-substituted phenyltriazole derivatives and uses thereof (2020-10-27),

9. 10526314 - Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof (2020-01-07),

10. 10525041 - Fluoroalkyl-substituted aryltriazole derivatives and uses thereof (2020-01-07),

11. 10519154 - 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof (2019-12-31),

12. 10472348 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2019-11-12),

13. 10435403 - Positive allosteric modulators of muscarinic M2 receptor (2019-10-08),

14. 9988367 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2018-06-05),

Title: Matthias Beat Wittwer: A Pioneer in Pharmaceutical Innovations

Introduction

Matthias Beat Wittwer, an esteemed inventor based in Riehen, Switzerland, has made significant contributions to the field of pharmaceutical research and development. With a remarkable portfolio of 14 patents, his work primarily focuses on innovative medicinal compounds aimed at treating various diseases, particularly cardiovascular and renal disorders.

Latest Patents

Among his latest patents, Wittwer has developed novel 7-substituted 1-arylnaphthyridine-3-carboxamides. These compounds are designed for the treatment and prevention of diseases, specifically targeting cardiovascular and renal disorders. Another notable invention is his work on prodrugs of substituted triazole derivatives, which offers potential treatments for similar health issues. The applications of these compounds highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Matthias Wittwer's career has been significantly shaped by his association with prominent pharmaceutical companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His involvement in these organizations has provided him with the platform to collaborate on cutting-edge research and contribute to groundbreaking advancements in medicinal chemistry.

Collaborations

Throughout his career, Wittwer has had the opportunity to work alongside distinguished colleagues, including Hanna Tinel and Thomas Neubauer. These collaborations have fostered a dynamic exchange of ideas and expertise, further enhancing the innovation stemming from his projects.

Conclusion

In summary, Matthias Beat Wittwer is a remarkable inventor whose extensive research and patent portfolio reflect his dedication to improving healthcare. His innovative work in developing novel pharmaceutical compounds holds the potential to make a significant impact on the treatment and prevention of serious health conditions, underscoring his importance in the field of pharmaceuticals.

Profile summary based on public USPTO records.